Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03161535
Other study ID # 2017-04-001A
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 19, 2017
Est. completion date July 2024

Study information

Verified date May 2023
Source Taipei Veterans General Hospital, Taiwan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate the effectiveness of a rehabilitation program in improving sleep quality, emotional distress, circadian rhythms, and quality of life in patients with esophageal cancer in Taiwan. Hypothesis: 1. The quality of life in exercise group is significant improving than usual-care group at 3rd, 6th, 12th, 24th, and 36th month. 2. The quality of sleep in exercise group is significant improving than usual-care group at 3rd, 6th, 12th, 24th, and 36th month. 3. The emotional distress in exercise group is significant improving than usual-care group at 3rd, 6th, 12th, 24th, and 36th month. 4. The circadian rhythms in exercise group is significant improving than usual-care group at 3rd, 6th, 12th, 24th, and 36th month.


Description:

This study will investigate the effectiveness of a rehabilitation program in improving sleep quality, emotional distress, circadian rhythms, and quality of life in patients with esophageal cancer in Taiwan.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 85
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Patients with esophageal cancer who were aged =20 years, could communicate in either Mandarin or Taiwanese, and were not cognitively impaired were included. Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Other:
exercise and dietary education
A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a week, was administered along with weekly exercise counseling. After collecting pretrial measurements, we explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. The detailed instructions, provided at the hospital clinics, included the determination of activity intensity, demonstration of pulse measurement, criteria for scores of 6-20 on the Borg's rating of perceived exertion (RPE), prevention of exercise-related injuries, and conditions necessitating termination of an exercise session. Participants were instructed that the exercises would be effective only if they reached 60%-80% of the target heart rate, as determined by the Karvonen method, and 13-15 on the RPE. Diet-teaching program (using dietary education booklet).
weekly telephone consultations concerning exercise and diet.
For each participant, we discussed exercise regimen-related issues and diet weekly through the telephone. For instance, we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.

Locations

Country Name City State
Taiwan National Taipei University of Nursing and Health Sciences Taipei

Sponsors (1)

Lead Sponsor Collaborator
Taipei Veterans General Hospital, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of life (EORTC QLQ-C30 ) using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. baseline
Primary Quality of life (EORTC QLQ-C30 ) using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. 3rd month after recruited
Primary Quality of life (EORTC QLQ-C30 ) using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. 6th month after recruited
Primary Quality of life (EORTC QLQ-C30 ) using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. 12th month after recruited
Primary Quality of life (EORTC QLQ-C30 ) using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. 24th month after recruited
Primary Quality of life (EORTC QLQ-C30 ) using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. 36th month after recruited
Primary Quality of life (EORTC QLQ-OES 18 ) using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. baseline
Primary Quality of life (EORTC QLQ-OES 18 ) using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. 3rd month after recruited
Primary Quality of life (EORTC QLQ-OES 18 ) using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. 6th month after recruited
Primary Quality of life (EORTC QLQ-OES 18 ) using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. 12th month after recruited
Primary Quality of life (EORTC QLQ-OES 18 ) using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. 24th month after recruited
Primary Quality of life (EORTC QLQ-OES 18 ) using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. 36th month after recruited
Secondary Subjective sleep quality using Pittsburgh Sleep Quality Index baseline
Secondary Subjective sleep quality using Pittsburgh Sleep Quality Index 3rd month after recruited
Secondary Subjective sleep quality using Pittsburgh Sleep Quality Index 6th month after recruited
Secondary Subjective sleep quality using Pittsburgh Sleep Quality Index 12th month after recruited
Secondary Subjective sleep quality using Pittsburgh Sleep Quality Index 24th month after recruited
Secondary Subjective sleep quality using Pittsburgh Sleep Quality Index 36th month after recruited
Secondary Objective sleep quality using Actigraph for measure Objective sleep quality baseline
Secondary Objective sleep quality using Actigraph for measure Objective sleep quality 3rd month after recruited
Secondary Objective sleep quality using Actigraph for measure Objective sleep quality 6th month after recruited
Secondary Objective sleep quality using Actigraph for measure Objective sleep quality 12th month after recruited
Secondary Objective sleep quality using Actigraph for measure Objective sleep quality 24th month after recruited
Secondary Objective sleep quality using Actigraph for measure Objective sleep quality 36th month after recruited
Secondary Emotional distress Emotional distress including anxiety and depression (Hospital Anxiety and Depression Scale). The Hospital Anxiety and Depression Scale include anxiety and depression subscales, a total of 7 questions, each subscale is a four-point scoring method, 0 point for "not at all", 3 points for "always do", each subscale scores is between 0 and 21, that a score of 7 or less for non-cases, scores of 8-10 for doubtful cases and scores of 11 or more for definite cases. baseline, 3rd month, 6th month, 12th month, 24th month, and 36th month after recruited
Secondary Circadian rhythms Circadian rhythms including 24-h autocorrelation coefficient (r24) and in bed less than out of bed dichotomy index (I baseline, 3rd month, 6th month, 12th month, 24th month, and 36th month after recruited
See also
  Status Clinical Trial Phase
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting NCT05542680 - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer N/A
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT00003864 - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus Phase 2
Recruiting NCT05491616 - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed NCT00400114 - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04615806 - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy N/A
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Terminated NCT01446874 - Prevention of Post-operative Pneumonia (POPP) Phase 2/Phase 3
Completed NCT03468634 - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy N/A
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT01404156 - Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma Phase 2/Phase 3